Data News > Top gainers in TOP US - Healthcare Companies - MRK, PFE
MRK is trading UP for the last 1 days, and it at trading at $118.58 with volume of 9,295,126 and a one day change of $2.78 (2.40%). Merck & Co Inc has a 52-week low of 99.14 and a 52-week high of $134.63. The business's 50-day moving average price is $117.89 and its 200 day moving average price is $125.13. The firm has a market cap of $294 million, a P/E ratio of 144.51, and a beta of 0.40.
The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss. Merck's business is growing, but the stock's gains have been modest this year. The drug manufacturer remains heavily reliant on Keytruda, which accounts for nearly half of its revenue. Venerable Coca-Cola has increased dividends for more than six decades. Merck's lifesaving treatments aren't affected by economic cycles.
For more information on MRK:
Historical Price Targets Hiistorical Analyst Recommendations Earning Price Impact Analysis Seasonality Analysis
PFE is trading UP for the last 2 days, and it at trading at $28.51 with volume of 21,579,816 and a one day change of $0.12 (0.42%). Pfizer Inc. has a 52-week low of 25.20 and a 52-week high of $36.29. The business's 50-day moving average price is $29.35 and its 200 day moving average price is $28.04. The firm has a market cap of $161 million, a P/E ratio of 0.00, and a beta of 0.62.
Investing in biotech and pharma stocks is certainly not for everyone, as these companies are vulnerable to various external risks. I turned bullish on Pfizer last January based on several reasons, including the expectations for a resumption in buybacks and the company's strategy shift to focus on profitable growth. A couple of days ago, Vaxcyte, a clinical-stage biotech company, reported promising results in a Phase 1/2 trial for its pneumococcal vaccine, threatening Prevnar, Pfizer's blockbuster drug. Pfizer's stock is undervalued with a 48% upside potential, supported by robust product pipelines, strategic initiatives, and a high 5.94% forward dividend yield. Recent pipeline developments, including new cancer treatments and promising vaccine results, highlight Pfizer's commitment to innovation and strategic partnerships. Q2 results exceeded expectations, with revenues of $13.28 billion and an adjusted EPS of $0.60, leading to an increased FY2024 revenue guidance.
For more information on PFE:
Historical Price Targets Hiistorical Analyst Recommendations Earning Price Impact Analysis Seasonality Analysis
Top gainers in TOP US - Healthcare Companies - MRK, PFE
By KlickAnalytics Data Insights | September 5, 2024 04:40PM ET
Following are the Top 5 companies based on their one-day percentage change within the 'TOP US - Healthcare Companies' theme.
Merck & Co Inc (MRK)
MRK is trading UP for the last 1 days, and it at trading at $118.58 with volume of 9,295,126 and a one day change of $2.78 (2.40%). Merck & Co Inc has a 52-week low of 99.14 and a 52-week high of $134.63. The business's 50-day moving average price is $117.89 and its 200 day moving average price is $125.13. The firm has a market cap of $294 million, a P/E ratio of 144.51, and a beta of 0.40.
Top news headlines for MRK
For more information on MRK:
Pfizer Inc. (PFE)
PFE is trading UP for the last 2 days, and it at trading at $28.51 with volume of 21,579,816 and a one day change of $0.12 (0.42%). Pfizer Inc. has a 52-week low of 25.20 and a 52-week high of $36.29. The business's 50-day moving average price is $29.35 and its 200 day moving average price is $28.04. The firm has a market cap of $161 million, a P/E ratio of 0.00, and a beta of 0.62.
Top news headlines for PFE
For more information on PFE:
This article was generated by KlickAnalytics data insight content engine.
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.